<DOC>
	<DOCNO>NCT02484703</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , efficacy , pharmacokinetic pharmacodynamic activity 3 different dosage RO5186582 compare placebo . A total approximately 46 participant enrol , order least 32 evaluable , randomly assign 1 4 treatment 1:1:1:1 ratio , 9 child per treatment arm . The target ratio 6-8 year 9-11 year age group approximately 1:1 treatment arm , minimum 3 child per age group treatment arm .</brief_summary>
	<brief_title>A Study RO5186582 Down Syndrome Among Children 6 11 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<criteria>Diagnosis Down syndrome , except mosaic Down syndrome Available parent caregiver attend clinic visit provide information participant 's behavior symptom Any primary psychiatric comorbid disorder History infantile spasm , West syndrome , LennoxGastaut syndrome , early infantile epileptic encephalopathy , treatmentrefractory epilepsy cognitive/developmental regression , severe head trauma , central nervous system ( CNS ) infection Seizure event type within 12 month prior Screening relevant change antiepileptic drug 6 week prior enrollment Significant sleep disruption Significant gastrointestinal , renal , hepatic , endocrine , cardiovascular disease Newonset ongoing hematologic/oncologic disorder Severe lactose intolerance Participation another clinical study within 1 month 6 halflives prior first dose , extent participation Study BP29589 ( NCT02451657 )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>